P.R. Herzig & Co. Inc. raised its position in GlaxoSmithKline PLC (NYSE:GSK) by 1.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,750 shares of the pharmaceutical company’s stock after buying an additional 700 shares during the period. GlaxoSmithKline PLC accounts for approximately 3.4% of P.R. Herzig & Co. Inc.’s holdings, making the stock its 10th largest position. P.R. Herzig & Co. Inc.’s holdings in GlaxoSmithKline PLC were worth $1,714,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of GSK. First Republic Investment Management Inc. raised its stake in shares of GlaxoSmithKline PLC by 30.7% in the first quarter. First Republic Investment Management Inc. now owns 39,201 shares of the pharmaceutical company’s stock worth $1,590,000 after buying an additional 9,208 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of GlaxoSmithKline PLC by 2.2% in the second quarter. BNP Paribas Arbitrage SA now owns 142,234 shares of the pharmaceutical company’s stock worth $6,164,000 after buying an additional 3,071 shares in the last quarter. Iowa State Bank raised its stake in shares of GlaxoSmithKline PLC by 4.6% in the second quarter. Iowa State Bank now owns 42,406 shares of the pharmaceutical company’s stock worth $1,838,000 after buying an additional 1,855 shares in the last quarter. Fulton Bank N.A. raised its stake in shares of GlaxoSmithKline PLC by 2.9% in the second quarter. Fulton Bank N.A. now owns 96,034 shares of the pharmaceutical company’s stock worth $4,162,000 after buying an additional 2,700 shares in the last quarter. Finally, Cullinan Associates Inc. raised its stake in shares of GlaxoSmithKline PLC by 44.5% in the second quarter. Cullinan Associates Inc. now owns 15,271 shares of the pharmaceutical company’s stock worth $662,000 after buying an additional 4,700 shares in the last quarter. 8.67% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded down 1.25% on Wednesday, reaching $37.79. The company had a trading volume of 5,655,904 shares. GlaxoSmithKline PLC has a 12 month low of $37.65 and a 12 month high of $45.58. The firm has a market capitalization of $91.94 billion, a PE ratio of 248.62 and a beta of 0.93. The firm’s 50 day moving average is $39.70 and its 200 day moving average is $42.31.

The company also recently declared a dividend, which will be paid on Thursday, January 12th. Shareholders of record on Friday, November 4th will be paid a dividend of $0.459 per share. The ex-dividend date is Wednesday, November 2nd. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 1,533.33%.

WARNING: “GlaxoSmithKline PLC (GSK) Stake Boosted by P.R. Herzig & Co. Inc.” was reported by Daily Political and is the propert of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this piece of content can be read at http://www.dailypolitical.com/2016/11/30/glaxosmithkline-plc-gsk-stake-boosted-by-p-r-herzig-co-inc.html.

GSK has been the subject of a number of research analyst reports. Beaufort Securities reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, August 2nd. Citigroup Inc. reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Wednesday, August 10th. Shore Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, August 11th. Argus lifted their target price on GlaxoSmithKline PLC from $48.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, August 12th. Finally, HSBC reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Monday, September 12th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $48.20.

In other news, major shareholder Plc Glaxosmithkline purchased 66,500 shares of the firm’s stock in a transaction on Monday, October 24th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $931,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 10.00% of the company’s stock.

About GlaxoSmithKline PLC

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.